Patients with certain fast-progressing and deadly types of acute myeloid leukemia (AML) saw the first new drug for their disease in more than 40 years approved by the FDA. Read More

The fourth one on the list of Moffitt research developments for 2017 involves rethinking drug resistance with a strategy called adaptive therapy that links the frequency, dosage and type of chemo to the tumor’s response. Read More

The third item on the list of Moffitt research developments for 2017 involves new targets for existing cancer-fighting drugs. Read More

What if a drug commonly used to protect bones from osteoporosis could be altered to keep out breast cancer cells? That’s the goal one Moffitt researcher is pursuing through the creation of "Smart Molecules." Read More

Dr. Susan Hoover, a surgical oncologist in the Breast Oncology Program at Moffitt Cancer Center, answers five questions about life after breast cancer. Read More

If you’re wondering what the difference is between a radiation oncologist and a radiologist, you’re not alone. Read More